Consensus Agenus Inc.

Stocks

AGEN

US00847G8042

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2026-10-16 EDT			5-day change	1st Jan Change
6.040 ^USD	-9.58%		-21.25%	+92.36%

10-08	Agenus Gets Armenia Approval for Botensilimab-Balstilimab Combination	MT
10-08	Agenus Inc. Receives Marketing Authorizations in Armenia for Botvymo and Evamplix for Use in Combination in Previously Treated Mss Metastatic Colorectal Cancer	CI

Evolution of the Average Target: Agenus Inc.

Evolution of the Target Price: Agenus Inc.

Changes in Analyst Recommendations: Agenus Inc.

0a2cf5.BV-M2KCtvqMmVjaRR8bFzmuF4q0je5BrVZgRu0DJcoY.ZA3kh5eehpBrJEHnMKK8uSLh2sx8EdkjJPZV0DGtAuhGFuCuxN_nkEphfw~1a1b4801963e6df749fdeb49ba59e901

Analysts' recommendations: Agenus Inc.

09-28	Agenus Shares Rise After Chardan Initiates Coverage at Buy	MT
09-18	Chardan Initiates Agenus at Buy With $40 Price Target	MT
07-30	B. Riley Adjusts Agenus Price Target to $14 From $8, Maintains Buy Rating	MT
25-06-04	HC Wainwright Upgrades Agenus to Buy From Neutral, $25 Price Target	MT
25-04-21	B. Riley Cuts Price Target on Agenus to $8 From $11, Keeps Buy Rating	MT
24-11-18	B. Riley Adjusts Agenus Price Target to $11 From $18, Maintains Buy Rating	MT
24-08-14	B. Riley Adjusts Price Target on Agenus to $18 From $42, Maintains Buy Rating	MT
24-07-19	HC Wainwright Downgrades Agenus to Neutral From Buy, Adjusts Price Target to $9 From $40	MT
24-07-19	William Blair Downgrades Agenus to Market Perform From Outperform	MT
24-07-19	Baird Downgrades Agenus to Neutral From Outperform, Adjusts Price Target to $8 From $35	MT
24-03-18	B. Riley Securities Trims Agenus' Price Target to $5 From $6 After Model Update, Maintains Buy Rating	MT
23-11-09	B. Riley Lowers Agenus' Price Target to $6 From $8, Maintains Buy Rating	MT
23-06-06	Baird Initiates Agenus at Outperform With $8 Price Target	MT
23-02-28	HC Wainwright Assumes Agenus at Buy With $8 Price Target	MT
22-12-22	EF Hutton Starts Agenus With Buy Rating, Sets Price Target at $8.30	MT
22-12-08	EF Hutton Initiates Agenus With Buy Rating, Price Target is $8.3	MT
22-09-28	SMBC Nikko Starts Agenus at Outperform With $5 Price Target	MT
22-03-03	B. Riley Lowers Agenus' Price Target to $8 from $11, Keeps Buy Rating	MT
22-03-02	HC Wainwright Adjusts Agenus' Price Target to $14 from $12, Reiterates Buy Rating	MT
21-12-16	HC Wainwright Starts Agenus at Buy With $12 Price Target	MT
21-09-07	Agenus : B. Riley Raises Agenus' PT to $12 from $11, Says Continued Regulatory Progress to Drive Stock Price Performance; Keeps Buy Rating	MT
21-06-29	Agenus : B. Riley Raises Agenus' PT to $11 from $8, Notes Value Accretive Catalysts; Keeps Buy Rating	MT

More recommendations

Other Biotechnology & Medical Research

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	AGENUS INC.					+335.98%
	WUXI APPTEC CO., LTD.					+32.97%
	LONZA GROUP AG					+14.74%
	ARGENX SE					+38.45%
	IQVIA HOLDINGS INC.					+12.07%
	BEONE MEDICINES AG					+18.26%
	REVOLUTION MEDICINES, INC.					+44.87%
	CELLTRION, INC.					+38.06%
	WUXI BIOLOGICS (CAYMAN) INC.					+24.78%
	GENMAB A/S					+8.87%
	Average					+56.91%
	Weighted average by Cap.					+26.98%